Response distributions for the questions that represent the latent variable ‘cautious sexual attitudes’. by Abigail A. Lee (19935335)

Fit statistics for CFA analysis of the latent variable “intent to vaccinate against HPV”. by Abigail A. Lee (19935335)

(A and B) ChIP-qPCR analysis of HSF2 binding to the indicated KSHV genomic regions expressed as % of input in KSHV infected latent (A) and lytic (B) cells. by Lorenza Cutrone (21144285)

Posterior distribution of the effect of the latent variable on the probability of seeking traditional remedies after a potential dog bite indicates a decreased likelihood of individuals seeking traditional remedies. by Philip P. Mshelbwala (11278898)

“…<p>Posterior distribution of the effect of the latent variable on the probability of seeking traditional remedies after a potential dog bite indicates a decreased likelihood of individuals seeking traditional remedies.…”

(A) Confocal representative images and (B) quantification of the H3me3K4 integrated intensity in n > 100 cells in iSLK.219 either latent or induced to the lytic cycle with doxycycl... by Lorenza Cutrone (21144285)

Probabilities of endorsing depressive symptoms derived from baseline 4-class latent class analysis (N = 619). by Carolin Oetzmann (11397968)

<i>Toxoplasma gondii</i> chronic infection decreases visceral nociceptive responses in the absence of macroscopic colonic inflammation. by Alexis Audibert (21213531)

Decreased visceral nociceptive responses induced by <i>Toxoplasma gondii</i> chronic infection relies on peripheral opioid signaling. by Alexis Audibert (21213531)

Participant retention flowchart. by Carolin Oetzmann (11397968)

“…We identified a 4-class solution: (1) severe with appetite decrease, (2) severe with appetite increase, (3) moderate severity and (4) low severity. …”

Model fit and class prevalence for baseline LCA models with varying numbers of classes and residual associations (N = 619). by Carolin Oetzmann (11397968)

Adjusted multinomial logistic regression models of class membership at baseline in relation to participant characteristics (N = 432). by Carolin Oetzmann (11397968)

Transition probabilities and class sizes for three-step LTA model (N = 432). by Carolin Oetzmann (11397968)

Data Sheet 1_Acute-phase proteins as biomarkers of inflammation in HIV patients with latent tuberculosis: a prospective study.pdf by Nathella Pavan Kumar (8911094)

“…</p>Results<p>Plasma levels of alpha-2-macroglobulin (A2M), C-reactive protein (CRP), serum amyloid P (SAP), haptoglobin, ferritin, soluble transferrin receptor (sTFR), apotransferrin, hepcidin, and S100A8/A9 were assessed using multiplex and quantikine assays.At baseline, levels of A2M, CRP, SAP, ferritin, hepcidin, and S100A9 were significantly elevated in HIV-positive patients with LTBI compared to those without LTBI (A2M, p=0.005; CRP, p<0.001; SAP, p=0.0006; ferritin, p<0.001; hepcidin, p=0.001; S100A9, p=0.001). …”

K1 expression decreases in HA15 treated cells. by Guillermo Najarro (19964572)

Using Penalized Synthetic Controls on Truncated Data: A Case Study on Effect of Marijuana Legalization on Direct Payments to Physicians by Opioid Manufacturers by Bikram Karmakar (6494186)

“…We provide evidence that this decrease is due to medical marijuana becoming available as a substitute. …”

Raw data of the charts in Fig 5. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Antibodies used in western blot analysis. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Raw data of the charts in Fig 3. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Raw data of the charts in Fig 1. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Raw data of the charts in Fig 6. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”